## RESEARCH



# Inositol 1,4,5-trisphosphate-induced Ca<sup>2+</sup> signalling is involved in estradiol-induced breast cancer epithelial cell growth

Cécilia Szatkowski<sup>1</sup>, Jan B Parys<sup>2</sup>, Halima Ouadid-Ahidouch<sup>1</sup> and Fabrice Matifat<sup>\*1</sup>

### Abstract

**Background:**  $Ca^{2+}$  is a ubiquitous messenger that has been shown to be responsible for controlling numerous cellular processes including cell growth and cell death. Whereas the involvement of IP<sub>3</sub>-induced Ca<sup>2+</sup> signalling (IICS) in the physiological activity of numerous cell types is well documented, the role of IICS in cancer cells is still largely unknown. Our purpose was to characterize the role of IICS in the control of growth of the estrogen-dependent human breast cancer epithelial cell line MCF-7 and its potential regulation by  $17\beta$ -estradiol (E<sub>2</sub>).

**Results:** Our results show that the  $IP_3$  receptor ( $IP_3R$ ) inhibitors caffeine, 2-APB and xestospongin C (XeC) inhibited the growth of MCF-7 stimulated by 5% foetal calf serum or 10 nM E<sub>2</sub>. Furthermore, Ca<sup>2+</sup> imaging experiments showed that serum and E<sub>2</sub> were able to trigger, in a Ca<sup>2+</sup>-free medium, an elevation of internal Ca<sup>2+</sup> in a 2-APB and XeC-sensitive manner. Moreover, the phospholipase C (PLC) inhibitor U-73122 was able to prevent intracellular Ca<sup>2+</sup> elevation in response to serum, whereas the inactive analogue U-73343 was ineffective. Western-blotting experiments revealed that the 3 types of IP<sub>3</sub>Rs are expressed in MCF-7 cells and that a 48 hours treatment with 10 nM E<sub>2</sub> elevated IP<sub>3</sub>R3 protein expression level in an ICI-182,780 (a specific estrogen receptor antagonist)-dependent manner. Furthermore, IP<sub>3</sub>R3 silencing by the use of specific small interfering RNA was responsible for a drastic modification of the temporal feature of IICS, independently of a modification of the sensitivity of the Ca<sup>2+</sup> release process and acted to counteract the proliferative effect of 10 nM E<sub>2</sub>.

Conclusions: Altogether, our results are in favour of a role of IICS in MCF-7 cell growth, and we hypothesize that the regulation of  $IP_3R3$  expression by  $E_2$  is involved in this effect.

### Background

 $Ca^{2+}$  is a ubiquitous messenger that has been shown to be responsible for controlling numerous cellular processes including muscle contraction, exocytosis, gene expression, cell growth and cell death [1-3]. Numerous studies have shown that Ca<sup>2+</sup> is involved in the control of cellular growth through its interaction with a plethora of intracellular proteins and cellular transduction pathways. The Ca<sup>2+</sup>-dependent processes are often involved in highly important cellular responses that are strikingly exemplified by their role in life-and-death decisions. Conse-

<sup>1</sup> Laboratoire de Physiologie Cellulaire et Moléculaire - JE-2530: Canaux ioniques et cancer du sein, Université d'Amiens, UFR des Sciences, 33 rue Saint-Leu 80039 Amiens, France

quently, Ca<sup>2+</sup> needs to be used in an appropriate manner to determine cell fate; if this balancing act is compromised, pathology may ensue [4]. In the case of malignant cells, the importance of Ca<sup>2+</sup> homeostasis has been demonstrated by studies showing that some highly phosphorylated inositol phosphates [5] and antagonists of the phosphoinositide pathway [6] or  $Ca^{2+}$  influx [7] arrest the growth of a variety of tumour cells in culture [8]. Furthermore, it has been shown that Ca<sup>2+</sup> plays a central role in vitamin D-induced cell death in cancerous cells [9-11]. Free intracellular Ca<sup>2+</sup> is provided by two main sources: i) extracellular, through a variety of Ca<sup>2+</sup> entry channels, ii) intracellular, from the endoplasmic reticulum (ER), mainly through two types of intracellular Ca<sup>2+</sup> channels [i.e. inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor (IP<sub>3</sub>R) and



© 2010 Szatkowski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-BioMed Central mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

<sup>\*</sup> Correspondence: fabrice.matifat@u-picardie.fr

Full list of author information is available at the end of the article

ryanodine receptor]. IP<sub>3</sub>R protein subtypes (namely IP<sub>3</sub>R1, IP<sub>3</sub>R2 and IP<sub>3</sub>R3) are encoded by three different genes in mammals but share high similarity in their primary sequences and are expressed to varying degrees in various cell types [12]. Even though they share common properties, it has been shown, however, that they are responsible for different types of Ca<sup>2+</sup> signals when expressed alone [13,14]. Temporal characteristics, that is amplitude, frequency and duration, of the Ca<sup>2+</sup> signal determine its intracellular function [15]. For example, it has been shown that the encoding of several genes is dependent on the oscillatory or transitory pattern of the Ca<sup>2+</sup> signal [16,17].

The steroid hormone  $17\beta$ -estradiol (E<sub>2</sub>) is a key growth regulator involved in normal breast development where it stimulates growth of the ductal system. However, clinical and experimental data have clearly established that exposure to estrogens is the leading cause of sporadic female breast cancer [18]. The predominant biological effects of  $E_2$  have traditionally been considered to be based on its interaction with intracellular estrogen receptors [19]. These act via the regulation of transcriptional processes, involving nuclear translocation, binding to specific estrogen responsive elements and ultimately regulate gene expression [20-23]. Furthermore,  $E_2$  has also been shown to be involved in cellular responses that do not require the stimulation of estrogen receptors (i.e. alternative or non-genomic pathway) [24,25]. Whereas the involvement of IP<sub>3</sub>-induced Ca<sup>2+</sup> signalling (IICS) in the physiological activity of numerous cell types is well documented, the role of IICS in cancer cells is still largely unknown. In the case of breast cancer cells, only a few studies have described the Ca2+ release mechanisms [26] and their potential modulation by  $E_2$  and anti-estrogens [27-30].

In this study, we investigate the potential involvement of  $E_2$  in regulating IICS in the estrogen-dependent MCF-7 cell line. We show that the expression level of IP<sub>3</sub>R3 is controlled by  $E_2$  in an estrogen receptor-dependent manner and that the growth of MCF-7 cells induced by  $E_2$  is sensitive to pharmacological inhibitors of IP<sub>3</sub>Rs. Furthermore, IP<sub>3</sub>R3 gene silencing using specific siRNA diminishes  $E_2$ -induced cell growth and changed the temporal feature of ATP-induced intracellular Ca<sup>2+</sup> signals. We conclude that IICS is involved in  $E_2$ -induced MCF-7 cell growth and that the regulation of IP<sub>3</sub>R3 expression could explain this effect.

#### Results

#### Serum and E<sub>2</sub> trigger Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive stores

As for many other cell types, the growth of MCF-7 cells is dependent on internal  $Ca^{2+}$  and these cells are able to

elicit intracellular Ca<sup>2+</sup> signals in response of multiple ligands [31]. When Fura-2-loaded MCF-7 cells were perfused in a Ca2+-free medium, serum was able to trigger Ca<sup>2+</sup> release (Figure 1Aa) from IP<sub>3</sub>-sensitive Ca<sup>2+</sup> pools since the internal Ca<sup>2+</sup> elevation was inhibited by 58.6  $\pm$ 15.3% (n = 56; P < 0.05) by the known  $IP_3R$  antagonist 2-APB (75  $\mu$ M; Figure 1Ab) [32]. In addition, the IP<sub>3</sub>R inhibitor XeC (25 µM) similarly inhibited serum-triggered IICS by 64.7 ± 11.7% (Figure 1Ac; n = 49; P < 0.05). To further assess the role of the IP<sub>3</sub>R in this process, we also used the phospholipase C inhibitor U-73122 (20 µM). The latter completely suppressed the seruminduced intracellular Ca2+ release (Figure 1Ad) whereas the inactive analogue U-73343 (20 µM) was ineffective (Figure 1Ad, inset). Finally, we also tested whether  $E_2$  was able to induce intracellular Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive stores. Indeed, in the absence of extracellular Ca<sup>2+</sup>,  $E_2$  (10 nM) evoked Ca<sup>2+</sup> signals (Figure 1Ba) that were inhibited for  $87.3 \pm 10.2\%$  (n = 52; P < 0.05) by 25  $\mu$ M XeC (Figure 1Bb).

## Pharmacological inhibitors of IP<sub>3</sub>-induced Ca<sup>2+</sup> signalling inhibited MCF-7 cell growth

In order to verify the possible involvement of IICS in MCF-7 cell growth, pharmacological inhibitors of IP<sub>3</sub>R (i.e. caffeine, 2-APB and XeC) were tested on 5-FCS- and E2-induced cell growth. As could be expected, cell counting using the trypan-blue exclusion method showed that 5-FCS was able to increase MCF-7 cell growth compared to a starvation culture medium (Figure 2A). Interestingly, both caffeine (500  $\mu$ M) and 2-APB (75  $\mu$ M) significantly inhibited cell growth in 5-FCS by  $23.0 \pm 6.2\%$  (P < 0.05; n = 18) and 76.2  $\pm$  5.4% (P < 0.001; n = 18), respectively. In all experiments, the total number of dead cells did not exceed 5%, thus the increase in cell number could be attributed to an increase of cell proliferation. Addition of E<sub>2</sub> in the culture medium similarly stimulated cell growth (Figure 2B). We tested the effect of caffeine on  $E_{2^-}$ induced growth. In this latter case, MCF-7 cells were seeded in 0-FCS for a 24 h period in order to eliminate all proliferative agents and were then stimulated with  $E_2$  for 48 h in the absence or the presence of caffeine (500  $\mu$ M). Figure 2B shows that caffeine was able to inhibit by  $66.7 \pm$ 3.1% the growth induced by 10 nM  $E_2$  (P < 0.01; n = 18). The cell growth in the presence of caffeine alone was not statistically different from that in 0-FCS (90.4  $\pm$  5.5%, n = 18 vs 100.0  $\pm$  6.8%, n = 18; P > 0.05). The effect of 2-APB could not be adequately tested as it triggered even under control conditions a significant elevation in cell death (>55%). Furthermore, as caffeine and 2-APB have been described as non-specific IP<sub>3</sub>R antagonists, we performed experiments using XeC, another IP<sub>3</sub>R inhibitor, in order



**Figure 1 Serum triggers an intracellular Ca<sup>2+</sup> signal**. (A) The perfusion of a Ca<sup>2+</sup>-free recording solution containing 5% of serum on Fura-2-loaded MCF-7 cells elicited a strong intracellular Ca<sup>2+</sup> signal (a). This signal was due to release from IP<sub>3</sub>-sensitive Ca<sup>2+</sup> stores as it was sensitive to previous application of 2-APB (75  $\mu$ M, b) or XeC (25  $\mu$ M, c). Furthermore, U-73122 (20  $\mu$ M) prevented the effect of serum on intracellular Ca<sup>2+</sup> release (d) whereas the inactive analogue U-73343 (20  $\mu$ M) was ineffective (d, inset). (B) E<sub>2</sub> (10 nM) triggered intracellular Ca<sup>2+</sup> elevations in MCF-7 cells perfused with a Ca<sup>2+</sup>-free medium (a); these Ca<sup>2+</sup> elevations were inhibited by XeC (25  $\mu$ M, b). In each panel, the results show the typical traces of 27 to 35 cells, always represented at the same scale; each time, also the mean signal is represented (thick black line).



**Figure 2** Pharmacological inhibitors of IP<sub>3</sub>Rs inhibited 5-FCS- and E<sub>2</sub>-induced MCF-7 cell growth. (A) The growth of MCF-7 cells induced by a 48 h treatment with 5-FCS was sensitive to pharmacological inhibitors of IP<sub>3</sub>R. Left bar graph shows the cell number obtained in 0-FCS and serves as a control experiment in order to estimate the proliferative effect of 5-FCS. Caffeine (500  $\mu$ M) and 2-APB (75  $\mu$ M) were both able to inhibit significantly 5-FCS-stimulated cell growth (P < 0.05 and P < 0.001, respectively). Values are the mean  $\pm$  S.E.M. of 6 independent experiments. (B) Pharmacological inhibition of IP<sub>3</sub>R was responsible for the inhibition of E<sub>2</sub>-induced cell growth. Whereas caffeine (500  $\mu$ M) was ineffective alone in control conditions, it inhibited the stimulation of cell growth by E<sub>2</sub> (10 nM, P < 0.01). Values are the mean  $\pm$  S.E.M. of 3 independent experiments. (C) XeC (10  $\mu$ M) inhibited both 5-FCS and E<sub>2</sub>-induced MCF-7 cell growth. Values are the mean  $\pm$  S.E.M. of 4 independent experiments. (D) Kinetics and reversibility of the inhibition by caffeine of E<sub>2</sub>-induced MCF-7 cell viability. Cells were starved for a 24 h period and were then stimulated by 10 nM E<sub>2</sub>. Caffeine (500  $\mu$ M) was either added (+caf) at the beginning of the experiment (a), or after 36 h (b). In both cases, caffeine inhibited the E<sub>2</sub>-induced increase in cell viability (P < 0.001). The effect of caffeine was reversible since washout (-caf) of this compound after 36 h permitted to significantly restore the proliferative effect of E<sub>2</sub> at 72 h (c). Arrows indicate the time of application (downward) or washout (upward) of caffeine. Values are the mean  $\pm$  S.E.M. of 3 independent experiments.

to increase the weight of evidence in support of a role for IICS in stimulating cell proliferation. A concentration of 10  $\mu$ M XeC was chosen in order to limit potential side effects of the compound during a long-term treatment; this concentration was verified to be sufficient to inhibit E<sub>2</sub>-induced Ca<sup>2+</sup> release (data not shown). Figure 2C shows that XeC (10  $\mu$ M) inhibited by 69.3 ± 7.1% (P < 0.05, n = 9) and by 71.0 ± 6.5% (P < 0.001, n = 9) the proliferation induced by 10 nM E<sub>2</sub> and 5-FCS, respectively.

Figure 2D demonstrates the kinetics and the reversibility of the inhibitory effect of caffeine on  $E_2$ -induced cell growth. Addition of caffeine (500 µM) at the beginning of the experiment or at intermediate time (0 h and 36 h, Figure 2Da and 2b, respectively) reduced the increase of cell viability induced by  $E_2$ . The inhibitory effect of caffeine on the  $E_2$ -induced cell growth is 46.7 ± 8.3% (P < 0.001; n = 27) at 36 h and 47.9 ± 8.4% (P < 0.001; n = 27) at 72 h (Figure 2Da). In the same way, the inhibition is 36.5 ± 6.7% (P < 0.001; n = 27) at 72 h when caffeine was added at the intermediate time (Figure 2Db). On the contrary, wash-out of caffeine at the intermediate time point significantly restored the proliferative effect of  $E_2$ ; the cell growth was in this case indeed  $31.3 \pm 4.5\%$  (P < 0.001; n = 27) higher compared to the condition in which caffeine was still present in the culture medium (Figure 2Dc).

#### Expression of IP<sub>3</sub>Rs isoforms and their regulation by E<sub>2</sub>

Considering these results showing the implication of IICS in MCF-7 cell growth, we carried out western-blotting experiments on MCF-7 microsomes in order to characterize the types of  $IP_3Rs$  expressed in these cells and the

potential effect of  $E_2$  on their expression level. Figure 3 shows that the 3 types of  $IP_3Rs$  are expressed. Whereas the expression level of  $IP_3R1$  and  $IP_3R2$  remained unchanged following a 48 h treatment with 10 nM  $E_2$  (Figure 3Aa, left and middle panel, respectively),  $E_2$  was able to elevate the expression level of  $IP_3R3$  (Figure 3Aa, right panel). Compared to control conditions, the expression level was 95.1 ± 14 (P > 0.05, n = 7) for  $IP_3R1$ , 107.5 ± 12 (P > 0.05, n = 7) for  $IP_3R2$  and 140.2 ± 11.3% (P < 0.05; n = 8) for  $IP_3R3$  (Figure 3Ba). Furthermore, this latter effect was counteracted by the specific antagonist of the estrogen receptor, ICI-182,780 (1  $\mu$ M; Figure 3Ab and





3Bb), a compound which is known to inhibit  $E_2$ -induced MCF-7 proliferation [[33] and data not shown].

## Silencing of IP<sub>3</sub>R3 by RNA interference limits the proliferative effect of E<sub>2</sub>

In order to further investigate the involvement of IP<sub>3</sub>R3 in E<sub>2</sub>-induced MCF-7 cell growth, the expression of IP<sub>3</sub>R3 in MCF-7 cells was silenced by the use of RNA interference. Figures 4A and 4B depict the efficiency of gene silencing at respectively the mRNA and the protein level following transfection of MCF-7 cells with a siRNA directed against IP<sub>3</sub>R3 (siR3) or a control siRNA (siC). At 24, 48 and 72 h post-transfection, siR3 reduced the IP<sub>3</sub>R3 mRNA by 68.7  $\pm$  7.4% (n = 3, P < 0.01), 69.8  $\pm$  6.3% (n = 3, P < 0.01) and  $66.2 \pm 5.7\%$  (n = 3, P < 0.01), respectively. Also at the protein level, siR3 induced a similar decrease in IP<sub>3</sub>R3 expression (Figure 4Bb). The expression of the IP<sub>3</sub>R3 was diminished by 70.8  $\pm$  9% (n = 3, P < 0.01), 88.6  $\pm$  6.3% (n = 3, P < 0.001) and 75.4  $\pm$  10.8% (n = 3, P < 0.01) at 24, 48 and 72 h respectively (Figure 4Bb). Treatment with siR3 had no effect on the expression levels of the other IP<sub>3</sub>R isoforms and no adaptation phenomenon occurred. Quantitative PCR experiments show that the level of IP<sub>3</sub>R1 and IP<sub>3</sub>R2 mRNA was not significantly changed  $(122.5 \pm 18.3\%; 95.9 \pm 7.2\%; 98.8 \pm 21.1 \text{ for IP}_3R1 \text{ and}$  $120.6 \pm 11.9\%$ ;  $105.0 \pm 4.8\%$ ;  $105.4 \pm 16.7\%$  for IP<sub>3</sub>R2 at 24, 48 and 72 h respectively, n = 3; Figure 4Ca). These latter results were confirmed by western-blotting experiments (Figure 4Cb). Compared to control, the level of  $IP_3R1$  and  $IP_{3}R2$  proteins was 105.0 ± 11.9%; 96.1 ± 14.2%; 108.2 ± 11.2 for IP<sub>3</sub>R1 and 108.9  $\pm$  5.2%; 102.3  $\pm$  9.8%; 104.4  $\pm$ 10.5% for  $IP_3R2$  at 24, 48 and 72 h, n = 4; respectively).

Subsequently, we tested the effect of siR3 on the  $E_{2^-}$ induced MCF-7 cell growth. Cells were transfected with either siC or siR3 and seeded in 5-FCS for 18 hours. After that, cells were starved for 6 h before being stimulated with 10 nM  $E_2$  for 48 hours. Whereas siR3 did not significantly modify the growth of MCF-7 cells in the absence of  $E_2$  (90.7 ± 9.1% of control; n = 27; P > 0.05), it appeared that siR3 was able to inhibit  $E_2$ -induced increase in cell number by 63.2 ± 6.7% (n = 27, P < 0.01, Figure 4C).  $E_2$ stimulated MCF-7 cell growth by 89.4 ± 18% (n = 27, P < 0.001) in siC-transfected cells and only by 32.9 ± 12.6% (n = 27; P > 0.05) in siR3-transfected cells. Taken together, this strongly suggests that the Ca<sup>2+</sup> signal resulting from the activation of IP<sub>3</sub>R3 is at least partly involved in the proliferative effect of  $E_2$ .

## $\rm IP_3R3$ silencing changed the temporal characteristics of intracellular Ca^{2+} signalling

We then determined the effect of  $IP_3R3$  silencing on the intracellular Ca<sup>2+</sup> signals in response to ATP. ATP delivers

very reproducible, standardized Ca<sup>2+</sup> signals that could be easily analyzed and quantified; furthermore, ATP is also able to stimulate MCF-7 proliferation [34]. Typical Fura-2 traces obtained after the perfusion of the cells with ATP (5  $\mu$ M) in a Ca<sup>2+</sup>-free medium after 72 hours of transfection with either siC or siR3 are depicted in Figure 5A. Decreased IP<sub>3</sub>R3 levels provoked a drastic change in the characteristics of the ATP-induced Ca2+ signal. Indeed, Ca<sup>2+</sup> signals changed from a plateau-type of response to a sinusoidal oscillatory-shaped signal. Statistical analysis revealed that at 24, 48 and 72 h post-transfection, the number of oscillating cells in response to ATP was much higher in siR3-transfected cells compared to siC-transfected cells (Figure 5B). The respective percentages of oscillating cells at 24, 48 and 72 h in siC-transfected cells versus siR3-transfected cells are  $15.6 \pm 4.4\%$  (n = 6) vs 56.1 ± 8.9% (n = 6, P < 0.001); 13.9 ± 2.5% (n = 6) vs 41.1 ± 5.4% (n = 6, P < 0.01) and 15.1  $\pm$  2.5% (n = 6) vs 78.3  $\pm$ 3.9% (n = 6, P < 0.001). In order to measure and compare the elevation of internal Ca2+ concentration in siC- and siR3-transfected MCF-7 cells, we calculated the "area under curve" (AUC) for each trace. Figure 5C represents typical Ca<sup>2+</sup> signals measured at 72 h post-transfection in both conditions after perfusion with 5  $\mu$ M ATP in a Ca<sup>2+</sup>free medium. Superimposition of both traces clearly suggests that despite the pattern of the Ca2+ signal was changed, the global amount of Ca<sup>2+</sup> released into the cell remained the same. This latter point was confirmed following statistical analysis. Indeed, the mean AUC values for Ca2+ signals elicited in siC-transfected cells versus siR3-transfected cells were not statistically different (Table 1) whatever the time post-transfection tested (24, 48 and 72 h).

#### IP<sub>3</sub>R3 silencing does not modify the sensitivity of IICS

To further uncover how calcium signalling is affected by down regulation of IP<sub>3</sub>R3 expression, the sensitivity of the calcium release process and the magnitude of the calcium release at maximal agonist concentration were investigated (Figure 6). We have therefore performed experiments using different ATP concentrations (ranging from 50 nM to 100 µM) in control (siC-transfected, Figure 6Aa) and in siR3-transfected MCF-7 cells (Figure 6Ab), 72 h after the transfection. Figure 6A clearly demonstrates that the sensitivity of the Ca<sup>2+</sup> release process remains virtually unchanged since the threshold for ATP (about 100 nM) is the same for both types of cells. Furthermore, the percentage of responding cells is unchanged in siC vs siR3-transfected cells (Figure 6Ac). Values are  $4.1 \pm 0.9\%$  vs  $3.8 \pm 0.8\%$  (P > 0.05);  $78.2 \pm 3.1\%$ vs 81.9 ± 2.8% (P > 0.05) and 94.3 ± 4.2% vs 95.5 ± 3.8% (P > 0.05) at 0.05, 0.1 and 0.5  $\mu$ M ATP, respectively. For higher ATP concentrations (i.e. 5 and 100  $\mu$ M) all the cells were responsive. However, the magnitude of the Ca2+ sig-



**Figure 4 Silencing of IP<sub>3</sub>R3 by RNA interference limits the proliferative effect of E<sub>2</sub>.** (A) Validation of the efficiency of the siRNAs used at the mRNA level (a, representative illustrations for 3 independent experiments). The IP<sub>3</sub>R3 mRNA level was lowered by about 70% (see text for details) at 24, 48 and 72 h post-transfection. (B) siR3 was responsible for a rapid and long-lasting diminution of the expression of IP<sub>3</sub>R3 at the protein level (a). Compared to control conditions, siR3 diminished the expression of IP<sub>3</sub>R3 at 24, 48 and 72 h (b). (C) Following IP<sub>3</sub>R3 silencing, the levels of IP<sub>3</sub>R1 and IP<sub>3</sub>R2 mRNA (a) and protein (b) were not significantly changed at 24, 48 and 72 h post-transfection. Representative blots for 3 to 4 independent western blotting experiments are shown. (D) MCF-7 cells were transfected with siC or siR3 and seeded for 18 h in 5-FCS and then starved for 6 h in 0-FCS. Cells were subsequently cultured in 0-FCS in the absence (-E<sub>2</sub>) of the presence (+E<sub>2</sub>) of E<sub>2</sub> (10 nM) for 48 h. MCF-7 cell number was measured at 72 h post-transfection using the trypan-blue exclusion method. E<sub>2</sub>-induced increase in cell number was strongly diminished in siR3-transfected MCF-7 cells compared to siC-transfected cells (P < 0.01).

| Time post-transfection | siRNA | Mean AUC $\pm$ SD (n) | P value |
|------------------------|-------|-----------------------|---------|
| 24 h                   | siC   | 16.8 ± 6.5 (77)       | 0.392   |
|                        | siR3  | 17.1 ± 6.5 (88)       |         |
| 48 h                   | siC   | 18.7 ± 4.5 (79)       | 0.112   |
|                        | siR3  | 19.5 ± 3.9 (83)       |         |
| 72 h                   | siC   | 16.6 ± 5.9 (89)       | 0.125   |
|                        | siR3  | 17.5 ± 4.2 (90)       |         |

#### Table 1: IP<sub>3</sub>R3 silencing does not modify the AUC of intracellular Ca<sup>2+</sup> signals

Statistical analysis of the effect of IP<sub>3</sub>R3 gene silencing on the AUC of Ca<sup>2+</sup> signals elicited by ATP (5  $\mu$ M) in Ca<sup>2+</sup>-free medium. At any time after the transfection, the global amount of Ca<sup>2+</sup> released as assessed from the AUC appears unchanged between the cells treated with siC or siR3.

nal (measurement of the AUC) is significantly diminished by  $18.4 \pm 5.7\%$  (n = 76, P < 0.01; Figure 6B) at maximal ATP concentration. Indeed, the mean AUC (arbitrary unit) is 21.4 ± 4.4 vs 22.3 ± 4.9 at 100 nM ATP; 54.2 ± 11.7 vs 49.6 ± 12.2 at 500 nM ATP; 132.8 ± 15.2 vs 138.1 ± 13.5 at 5  $\mu$ M ATP; and 184.4 ± 8.5 vs 150.5 ± 6.5 at 100  $\mu$ M ATP, for siC- versus siR3-transfected cells, respectively. Finally, our results clearly demonstrate that the main difference between the cell types is the dramatic increase in the percentage of cells demonstrating an oscillating Ca2+ signal pattern at all submaximal ATP concentrations after  $IP_3R3$  down regulation (Figure 6C): the mean percentage of cells demonstrating an oscillating pattern increased from 5.1 ± 0.9% to 33.3 ± 2.7% at 100 nM ATP; from 16.1  $\pm$  1.9% to 41.4  $\pm$  3.5% at 500 nM ATP and from 15.2  $\pm$ 2.5% to 78.3  $\pm$  3.9% at 5  $\mu$ M ATP, at each concentration in siC and siR3-transfected cells, respectively.

### Discussion

We showed in this study that MCF-7 cells express the 3 IP<sub>3</sub>R isoforms and that intracellular Ca<sup>2+</sup> release through these channels plays a role in the control of the growth of these cells. Indeed, using both pharmacological inhibitors and specific small inhibitory RNAs, we showed that IICS is involved in the increase in cell growth in response to addition of serum or E2. Our results are in agreement with previous studies showing that intracellular Ca<sup>2+</sup> elevation following ER emptying is crucial in order to ensure the activation by  $E_2$  of various protein kinases involved in cell cycle, such as mitogen-activated protein kinase, and to trigger MCF-7 cell proliferation [35]. In the same way, numerous studies have shown that IICS was responsible for stimulating the proliferation of various cell types [2] such as cerebral artery smooth muscle cells [36] and mouse cholangiocytes [37]. It has also been shown in gas-

tric cancer cells that 2-APB inhibits cell proliferation and that IP<sub>3</sub>R3 belongs to genes that are over expressed in the case of peritoneal dissemination [38]. In the case of breast cancer, a few studies have shown that IP<sub>3</sub>R could be the target of a variety of proteins such as Bcl-2 and cyclins that might affect cell viability by respectively suppressing apoptosis [29,30] and probably stimulating proliferation [39]. Interestingly, this study demonstrates that IP<sub>3</sub>R3 expression is up regulated by E2. Moreover, this regulation occurs in an estrogen receptor-dependent manner since it was sensitive to ICI-182,780, a compound known to inhibit E2-induced MCF-7 cell proliferation [33]. As the proliferative effect of E<sub>2</sub> involves IICS, we hypothesized that this could be, at least in part, due to the increased IP<sub>3</sub>R3 expression. This result is strengthened by the numerous studies showing a potential regulation of the expression level of IP<sub>3</sub>Rs by many factors, such as retinoic acid, TGF- $\beta$  or phorbol esters [see 40 for review]. In particular, expression of IP<sub>3</sub>R isoforms has been shown to be controlled by steroids such as progesterone and E<sub>2</sub> [41-43] or glucocorticoids [44]. Furthermore, an increased expression of IP<sub>3</sub>Rs has been described in proliferating arterial smooth muscle cell [45]. Other studies have already shown that the relative expression of the different IP<sub>3</sub>R isoforms is responsible for generating various Ca<sup>2+</sup> signals in term of duration, amplitude and shape (i.e. transient or oscillatory) [13]. For example, it has been shown that IP<sub>3</sub>R3 functions as an anti Ca<sup>2+</sup>-oscillatory unit in DT-40 cells [13] and in HeLa and COS-7 cells [14]. In full agreement with this, we demonstrated, on the basis of the results obtained using siRNA, that changing the IP<sub>3</sub>R3 levels in MCF-7 cells drastically changed the characteristics of the Ca2+ signals. Importantly, no



Figure 5 IP<sub>3</sub>R3 silencing changed the characteristics of ATP-induced Ca<sup>2+</sup> signalling in MCF-7 cells. (A) Typical ATP-induced Ca<sup>2+</sup> signals in MCF-7 cells 72 h after their transfection with siC (a) or siR3 (b). ATP (5 µM) was perfused in a Ca2+-free recording solution in order to avoid Ca<sup>2+</sup> entry. The Ca<sup>2+</sup> response changed from a plateau-type pattern to a characteristic oscillatory pattern in siR3-transfected cells. Representative for 6 independent experiments. (B) Statistical analysis of the effect of IP<sub>3</sub>R3 silencing at 24, 48 and 72 h post-transfection on the percentage of oscillating cells in response to 5  $\mu M$  ATP in a Ca2+-free recording solution. IP<sub>3</sub>R3 gene silencing resulted, at any time, in a strong augmentation of the percentage of cells that respond to ATP by an oscillatory Ca<sup>2+</sup> signal. (C) Typical ATP-induced Ca<sup>2+</sup> signals recorded in a Ca<sup>2+</sup>-free medium 72 h after transfection with siC (a) or siR3 (b). Ca<sup>2+</sup> signals presented in a (full line) and b (dotted line) were superimposed in order to clearly show the modification of the pattern of the Ca<sup>2+</sup> response (c).

changes occurred in the sensitivity of the Ca<sup>2+</sup> signals to ATP after down-regulation of IP<sub>3</sub>R3, which is probably due to the expression of IP<sub>3</sub>R1 and IP<sub>3</sub>R2 which have a higher affinity for IP<sub>3</sub> [13]. At maximal ATP stimulation, a small decrease in total Ca<sup>2+</sup> release was observed, but the largest difference was the profound increase (3- to 7-fold, depending on the ATP concentration used) in the number of cells displaying a pattern of sinusoidal Ca<sup>2+</sup> oscillations instead of a plateau phase. This fully supports the hypothesis that E<sub>2</sub> partly controls MCF-7 cell growth by encoding specific Ca<sup>2+</sup> signals through the IP<sub>3</sub>R3. A relation between Ca<sup>2+</sup> oscillation frequency and transcription factors has already been shown [16,17]. It can therefore



be hypothesized that the decrease in cell proliferation following  $IP_3R3$  silencing could be related to the modification of the temporal feature of the Ca<sup>2+</sup> signal.

Our results obtained following  $IP_3R3$  silencing show that basal MCF-7 proliferation in serum-deprived medium is not affected. This is due to the fact that in those conditions there is no factor present that can trigger internal Ca<sup>2+</sup> release. We have previously observed [24] a similar phenomenon in MCF-7 cells where iberiotoxin, an inhibitor of the voltage- and Ca<sup>2+</sup>-dependent K<sup>+</sup> channel BK, could impair the proliferation induced by  $E_2$  but not in basal conditions (0 FCS). Indeed, in the latter condition, basal  $Ca^{2+}$  activity is probably too low to ensure the activation of the BK channels while after induction with  $E_2$ , the internal  $Ca^{2+}$  level is sufficiently elevated to activate these channels and therefore to uncover the sensitivity to iberiotoxin.

Interestingly, our study demonstrates a link between IP<sub>3</sub>R3 expression and cellular proliferation, though IP<sub>3</sub>R3 has also been previously implicated in cell death [46]. It is thought that IP<sub>3</sub>Rs and IICS can convey and/or enhance cell death signals by allowing for an efficient Ca2+ shuttling between ER and mitochondria leading to mitochondrial Ca<sup>2+</sup> overload (see [47] for review). This efficient shuttling is only possible when the IP<sub>3</sub>R is closely apositioned to the mitochondria through physical interaction e.g. with the mitochondrial voltage-dependent anion channel. Several proteins can participate in this interaction, including glucose-regulated protein 75 and the sigma receptor Sig-1R [47]. This increased apoptosis does not seem to occur in the MCF-7 cells, what may be due either to the nearly complete absence of Sig-1R in those cells [48], or to additional regulation limiting the extent of Ca<sup>2+</sup> release and Ca<sup>2+</sup> transfer into mitochondrion by anti-apoptotic proteins as protein kinase B [49] or Bcl-2 [50]. Interestingly, the expression of the latter protein is up regulated by  $E_2$  in MCF-7 cells [51].

These various mechanisms may explain why, even though IP<sub>3</sub>R3 expression is increased in response to  $E_2$ , apoptosis is not stimulated. The increased proliferation can therefore be due to each or both of the following elements, (1) a stimulation of cell metabolism and ATP production by a low to intermediate flux of Ca<sup>2+</sup> to the mitochondria, large enough to stimulate the Ca<sup>2+</sup>-sensitive mitochondrial dehydrogenases but not to cause detrimental effects and (2) Ca<sup>2+</sup> signals with a temporal pattern able to activate more efficiently transcription factors acting on the expression of genes involved in proliferation.

In conclusion, our observations indicate that the growth of MCF-7 human breast cancer cells induced by  $E_2$  is sensitive to pharmacological inhibitors of IP<sub>3</sub>Rs. Moreover,  $E_2$  treatment induced an upregulation of IP<sub>3</sub>R3 in an estrogen receptor-dependent manner while IP<sub>3</sub>R3 gene silencing affected both intracellular Ca<sup>2+</sup> signalling and cellular proliferation. Taken together, these results are suggestive in MCF-7 cells for a regulation of cell growth by specific Ca<sup>2+</sup> signals, but further work is needed to elucidate the precise mechanism(s) involved.

### **Materials and Methods**

#### Cell culture

The MCF-7 cell line was purchased from the American Type Culture Collection (ATCC<sup>°</sup> HTB-22<sup>™</sup>, LGC Pro-

mochem) and cells were used for a maximum of 10 passages after receipt or resuscitation. Cells were grown in an atmosphere saturated with humidity at 37°C and 5%  $CO_2$  in Eagle's Minimal Essential Medium supplemented with 2 mM L-glutamine, 0.06% HEPES Buffer and a mixture of penicillin (50 UI/ml)/streptomycin (50 µg/ml). In addition, the culture medium was either supplemented with 5% FCS (5-FCS) or not supplemented with FCS (0-FCS) and was renewed every two days.

### **Cell viability**

For cell growth assays, 75,000 MCF-7 cells were seeded in Petri dishes (diameter 60 mm) in 5-FCS. After 48 h, cells were incubated in a phenol-red-free 0-FCS for a 24 h starvation period. Cells were then washed and incubated with  $E_2$  (10 nM) or 5-FCS, alone or in association with caffeine (500  $\mu M)$  or 2-APB (75  $\mu M).$  After 2 days of treatment, the cell number was determined by trypan blue exclusion method. The counts were replicated six times and the experiments were repeated at least three times. Alternatively, cell viability was measured by the use of the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide reduction assay (MTT-assay) [52]. In brief, MCF-7 cells were plated in 6-well plates at 5.10<sup>4</sup> cells per well and allowed to grow for 48 h. Cells underwent a 24 h starvation in 0-FCS and were then stimulated with 10 nM  $E_2$  in the presence or the absence of caffeine  $(500 \,\mu\text{M})$  for 36 h and 72 h. On the day of assay, treatment medium was replaced with medium containing 0.5 mg/ ml of MTT and incubated for 1 h at 37°C. Medium was then aspirated off and 800 µl of DMSO was added to solubilise crystals. The optical density of each sample was read on a microplate reader (MRX II; Revelation software 4.22) at 570 nm against a blank prepared from cell-free wells.

### Ca<sup>2+</sup> imaging

MCF-7 cells were cultured at 5.10<sup>4</sup> cells per dish on glass cover slips and cells were loaded for 1 h with Fura-2/AM (3  $\mu$ M in saline solution) at 37°C in a CO<sub>2</sub> incubator and subsequently washed three times with the dye-free recording solution. The cover slip was then transferred into a perfusion chamber of a Zeiss inverted microscope equipped for fluorescence. Fluorescence was excited at 340 and 380 nm alternately, using a monochromator (Polychrome IV; TILL Photonics), and captured by a Cool SNAP HQ camera (Princeton Instruments) after filtration through a long-pass filter (510 nm). Background fluorescence was determined at 340 and 380 nm from an area of the cover slip free of cells. These values were routinely subtracted. Metafluor software (v.6.2; Universal Imaging, West Chester, PA) was used for acquisition and analysis. All recordings were carried out at room temperature (RT; 20-22°C). The cells were continuously perfused with the saline solution, and chemicals were added via the perfusion system. The flow rate of the whole-chamber perfusion system was set at 10 ml/min, and the chamber volume was 1 ml. Recording solution had the following composition (in mM): NaCl 145, KCl 5, CaCl<sub>2</sub> 2, MgCl<sub>2</sub> 1, and Hepes 10 at pH 7.4 (NaOH). In experiments where Ca<sup>2+</sup>-free solution was used, Ca<sup>2+</sup> was omitted and EGTA (1 mM) was added to the solution. The "Area Under Curve" (AUC) was calculated using OriginPro v.8 and permitted to measure the global amount of Ca<sup>2+</sup> released into the cells following stimulation.

### Western Blotting

Cells were washed twice with phosphate-buffered saline (PBS) and lysed by addition of RIPA buffer (200  $\mu$ l/60 mm dish) containing protease inhibitor cocktail (Sigma P8340, 8  $\mu$ l/ml). After 30-45 min incubation on ice, the cell lysates were scraped off the Petri dish and transferred to 1.5 ml tubes. The extracts were then centrifuged at  $10,000 \times g$  for 10 min at 4°C in a table-top centrifuge and the supernatants were saved for analysis. For the determination of the effect of  $E_2$  on the expression level of the various IP<sub>3</sub>R isoforms, microsomal preparations from MCF-7 cells were performed according to an earlier published procedure [53]. Protein concentration was determined using the BCA method and the amount of lysates or of microsomes corresponding to 50 µg of protein was denatured with SDS sample buffer and separated on 4-15% precast SDS-polyacrylamide gels (Bio-Rad). Proteins were then transferred overnight at 4°C to Immobilon-P PVDF membranes (0.6 mA/cm<sup>2</sup> constant current; Bio-Rad) in Tris-glycine buffer without methanol. Transfer membranes were incubated for 1 h at RT in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and 5% dry milk and then incubated overnight at 4°C in primary antibodies: goat anti- $\beta$ -actin (1/2,000; Santa Cruz) as loading control, rabbit anti-IP<sub>3</sub>R1 (Rbt03, 1/1,000) [54]; rabbit anti-IP<sub>3</sub>R2 (CT2, 1/30) [55]; purified mouse anti-IP<sub>3</sub>R3 (610313; 1/2,000; BD Bioscience). Following primary antibody probing, the membranes were washed three times with TBS-T and incubated for 1 h at RT with the respective secondary horseradish-peroxidase-conjugated antibodies (Santa Cruz): anti-mouse (1/5,000) was used for the detection of IP<sub>3</sub>R3, anti-rabbit (1/5,000) for IP<sub>3</sub>R1 and IP<sub>3</sub>R2 and anti-goat (1/5,000) was used for the detection of  $\beta$ -actin. Proteins were visualized using the enhanced chemiluminescence system (Amersham) on a Chemidoc Apparatus and quantification was realized using Quantity One software.

## Total RNA isolation, reverse transcription of RNA and PCR experiments

Total RNA from MCF-7 cells was extracted by the Trizolphenol-chloroform (Sigma Aldrich) procedure, including DNAse I treatment (0.2 U/µl, 30 min at 37°C, Promega). Total RNA was then reverse-transcribed into cDNA using oligodT primers and MultiScribe<sup>™</sup> reverse transcriptase (Applied Biosystems). PCR experiments were carried out on an iCycler thermal cycler (Bio-rad) using Taq DNA polymerase (Invitrogen). PCR products were analysed by electrophoresis on 1.5% agarose gel and visualized by ethidium bromide staining. Finally, PCR products were quantified using Quantity One software and expressed as the ratio of IP<sub>3</sub>Rs on β-actin reference gene.

### **Cell transfection**

MCF-7 cells were collected after trypinization and submitted to electroporation using a Gene Pulser<sup>\*</sup> apparatus according to the manufacturer's instructions. Briefly, 2.10<sup>6</sup> cells were transfected with 2 µg siRNA directed against the human IP<sub>3</sub>R3 mRNA sequence (ON-TAR-GETplus, Dharmacon) or control siRNA (siGENOME non-targeting siRNA; Dharmacon). After the electroporation (program E-14), 500 µl of prewarmed culture medium were added and cells were transferred to a 1.5 ml tube and placed at 37°C for 15 min in a CO<sub>2</sub> incubator. After that, cells were seeded in Petri dishes (diameter 60 mm). 18 h later, cells were treated for 6 h in 0-FCS and were then stimulated with  $E_2$  (10 nM) for 48 h.

### Statistical analysis

Results were expressed as mean  $\pm$  S.E.M. Experiments were repeated at least three times. The Student's t-test was used to compare treatment means with control means. Statistical significance is indicated in the figures (NS, not significant; \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001).

### Reagents

All the products were from Sigma (France) unless otherwise stated. Final concentrations were obtained by appropriate dilution of stock solutions so that the solvent never exceeded 1/1,000.

### **Abbreviations used**

IP<sub>3</sub>: inositol 1,4,5-trisphosphate; IP<sub>3</sub>R: IP<sub>3</sub> receptor; IICS: IP<sub>3</sub>-induced Ca<sup>2+</sup> signalling; E<sub>2</sub>: 17β-estradiol; 2-APB: 2aminoethoxydiphenyl borate; XeC: xestospongin C; FCS: foetal calf serum; 5-FCS: culture medium containing 5% FCS; 0-FCS: serum-deprived culture medium; ER: endoplasmic reticulum.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Authors' contributions

CS performed experiments and analysed the data. JBP and HOA participated in the design of the study and helped to draft the manuscript. FM conceived and performed experiments, analysed the data and drafted the article. All authors read and approved the paper.

#### Acknowledgements

Financial support for CS was from « la Région Picardie », and financial support for this work was from le Ministère de l'Enseignement Supérieur et de la Recherche and l'Association pour la Recherche sur le Cancer (ARC) for FM and HOA and by the Concerted Actions of the K.U.Leuven for JBP. Authors wish to thank Pr. Richard J.H. Wojcikiewicz for the kind gift of anti-IP<sub>3</sub>R2 antibody. We also thank Pr. Sir Michael J. Berridge for critical reading of the manuscript and the suggestion of the experiments concerning the reversibility of the effect of caffeine on cell viability.

#### **Author Details**

<sup>1</sup>Laboratoire de Physiologie Cellulaire et Moléculaire - JE-2530: Canaux ioniques et cancer du sein, Université d'Amiens, UFR des Sciences, 33 rue Saint-Leu 80039 Amiens, France and <sup>2</sup>Laboratory of Molecular and Cellular Signalling, Department of Molecular and Cellular Biology, Campus Gasthuisberg O/N1- bus 802 - K U Leuven, Herestraat 49, B-3000 Leuven, Belgium

#### Received: 21 October 2009 Accepted: 21 June 2010 Published: 21 June 2010

#### References

- Berridge MJ: Calcium signalling and cell proliferation. *Bioessays* 1995, 17:491-500.
- 2. Berridge MJ, Lipp P, Bootman MD: The versatility and universality of calcium signalling. *Nature Rev* 2000, 1:11-21.
- 3. Berridge MJ: Inositol trisphosphate and calcium signalling mechanisms. *Biochim Biophys Acta* 2009, **1793**:933-940.
- Roderick HL, Cook SJ: Ca<sup>2+</sup> signalling checkpoints in cancer: remodelling Ca<sup>2+</sup> for cancer cell proliferation and survival. *Nature Rev* 2008, 8:361-375.
- Vucenik I, Ramakrishna G, Tantivejkul K, Anderson LM, Ramljak D: Inositol hexaphosphate (IP<sub>6</sub>) blocks proliferation of human breast cancer cells through a PKCδ-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. *Breast Cancer Res and Tr* 2005, 91:35-45.
- 6. Powis G, Phil D: Inhibitors of phosphatidylinositol signalling as antiproliferative agents. *Cancer Metast Rev* 1994, **13**:91-105.
- Cole K, Kohn E: Calcium-mediated signal transduction: biology, chemistry and therapy. Cancer Metast Rev 1994, 13:31-44.
- Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ: Calcium and cancer: targeting Ca<sup>2+</sup> transport. Nat Rev Cancer 2007, 7:519-530.
- Sergeev IN: Calcium as a mediator of 1,25-dihydroxyvitamin D3induced apoptosis. J Steroid Biochem Mol Biol 2004, 90:419-425.
- Sergeev IN: Calcium signaling in cancer and vitamin D. J Steroid Biochem Mol Biol 2005, 97:145-151.
- Sergeev IN: Genistein induces Ca<sup>2+</sup>-mediated, calpain/caspase-12dependent apoptosis in breast cancer cells. *Biochem Biophys Res Commun* 2004, **321**:462-467.
- Foskett JK, White C, Cheung KH, Mak DO: Inositol trisphosphate receptor Ca<sup>2+</sup> release channel. *Physiol Rev* 2007, 87:593-658.
- Miyakawa T, Maeda A, Yamazawa T, Hirose K, Kurosaki T, Iino M: Encoding of Ca<sup>2+</sup> signals by diffential expression of IP<sub>3</sub> receptor subtypes. *EMBO J* 1999, 18:1303-1308.
- Hattori M, Suzuki A, Higo T, Miyauchi H, Michikawa T, Nakamura T, Inoue T, Mikoshiba K: Distinct roles of inositol 1,4,5-trisphosphate receptor types 1 and 3 in Ca<sup>2+</sup> signalling. *J Biol Chem* 2004, 279:11967-11975.
- Lipskaia L, Lompré AM: Alteration in temporal kinetics of Ca<sup>2+</sup> signalling and control of growth and proliferation. *Biol Cell* 2004, 96:55-68.
- Li W, Llopis J, Whitney M, Zlokarnic G, Tsien RY: Cell-permeant caged-InsP<sub>3</sub> ester shows that Ca<sup>2+</sup> spike frequency can optimize gene expression. *Nature* 1998, 392:936-941.
- Dolmetsch RE, Xu K, Lewis RS: Calcium oscillations increase the efficiency and specificity of gene expression. *Nature* 1998, 392:933-936.
- Henderson IC: Risk factors for breast cancer development. Cancer 1993, 71:2127-4210.
- Platet N, Cathiard AM, Gleizes M, Garcia M: Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004, 51:55-67.

- Huang J, Li X, Yi P, Hilf R, Bambara RA, Muyan M: Targeting estrogen responsive elements (EREs): design of potent transactivators for EREcontaining genes. *Mol Cell Endocrinol* 2004, 218:65-78.
- Foster JS, Henley DC, Ahamed S, Wimalasena J: Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001, 12:320-327.
- 22. Dukik D, Shiu RP: Mechanisms of estrogen activation of c-myc oncogene expression. *Oncogene* 1992, **7:**1587-1594.
- Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL: c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Re-entry. Mol Cell Biol 1998, 18:4499-4508.
- 24. Coiret G, Matifat F, Hague F, Ouadid-Ahidouch H: **17-beta-estradiol** activates maxi-K channels through a non-genomic pathway in human breast cancer cells. *FEBS Lett* 2005, **579**:2995-3000.
- Walsh DE, Dockery P, Doolan CM: Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca<sup>2+</sup>]<sub>i</sub> in human breast cancer cells. *Mol Cell Endocrinol* 2005, 230:23-30.
- DeWald DB, Torabinejad J, Samant RS, Johnston D, Erin N, Shope JC, Xie Y, Welch DR: Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. *Cancer Res* 2005, 65:713-717.
- 27. Taylor JA, Grady LH, Engler KS, Welshons WV: Relationship of growth stimulated by lithium, estradiol, and EGF to phospholipase C activity in MCF-7 human breast cancer cells. *Breast Cancer Res Tr* 1995, 34:265-277.
- Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ: Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. *Steroids* 2006, 71:256-265.
- Bollig A, Xu L, Thakur A, Wu J, Kuo TH, Liao JD: Regulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifeninduced cytotoxicity. *Mol Cell Biochem* 2007, 305:45-54.
- Xu L, Kong D, Zhu L, Zhu W, Andrews DW, Kuo TH: Suppression of IP<sub>3</sub>mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase-1. *Mol Cell Biochem* 2007, 295:153-165.
- Patel KV, Schrey MP: Activation of Inositol Phospholipid Signaling and Ca<sup>2+</sup> Efflux in Human Breast Cancer Cells by Bombesin. *Cancer Res* 1990, 50:235-239.
- Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshiba K: 2APB, 2aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P<sub>3</sub>-induced Ca<sup>2+</sup> release. *J Biochem* 1997, 122:498-505.
- 33. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. *Cancer Research* 1991, **51**:3867-73.
- Dixon CJ, Bowler WB, Fleetwood P, Ginty AF, Gallagher JA, Carron JA: Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. Br J Cancer 1997, 75:34-39.
- Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP: Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. *Proc Natl Acad Sci USA* 1999, 96:4686-4691.
- Wilkerson MK, Heppner TJ, Boney AD, Nelson MT: Inositol trisphosphate receptor calcium release is required for cerebral artery smooth muscle cell proliferation. *Am J Physiol Heart Circ Physiol* 2006, 290:240-247.
- 37. Francis H, Glaser S, DeMorrow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marzioni M, Vaculin S, Vaculin B, Katki K, Stutes M, Savage J, Alpini G: Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP<sub>3</sub>/CaMKI/ CREB pathway. Am J Physiol Cell Physiol 2008, 295:499-513.
- Sakakura C, Hagiwara A, Fukuda K, Shimomura K, Takagi T, Kin S, Nakase Y, Fujiyama J, Mikoshiba K, Okazaki Y, Yamagishi H: Possible involvement of inositol 1,4,5-trisphosphate receptor type 3 (IP<sub>3</sub>R3) in the peritoneal dissemination of gastric cancers. *Anticancer Res* 2003, 23:3691-3697.
- Soghoian D, Jayaraman V, Silane M, Berenstein A, Jayaraman T: Inositol 1,4,5-trisphosphate receptor phosphorylation in breast cancer. *Tumour Biol* 2005, 26:207-212.
- Taylor CW, Genazzani AA, Morris SA: Expression of Inositol trisphosphate receptors. Cell Calcium 1999, 26:237-251.
- Mesonero JE, Tanfin Z, Hilly M, Colosetti P, Mauger JP, Harbon S: Differential expression of Inositol 1,4,5-trisphosphate receptor types 1, 2 and 3 in rat myometrium and endometrium during gestation. *Biol Reprod* 2000, 63:532-537.

- Kirkwood KL, Dziak R, Bradford PG: Inositol trisphosphate receptor gene expression and hormonal regulation in osteoblast-like cell lines and primary osteoblastic cell cultures. J Bone Miner Res 1996, 11:1889-1895.
- Kirkwood KL, Homick K, Dragon MB, Bradford PG: Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter. Regulation by 17beta-estradiol in osteoblasts. *J Biol Chem* 1997, 272:22425-22431.
- 44. Davis MC, McColl KS, Zhong F, Wang Z, Malone MH, Distelhorst CW: Dexamethasone-induced inositol 1,4,5-trisphosphate receptor elevation in murine lymphoma cells is not required for dexamethasone-mediated calcium elevation and apoptosis. *J Biol Chem* 2008, 283:10357-10365.
- Berra-Romani R, Mazzocco-Spezzia A, Pulina MV, Golovina VA: Ca<sup>2+</sup> handling is altered when arterial myocytes progress from a contractile to a proliferative phenotype in culture. *Am J Physiol Cell Physiol* 2008, 295:779-790.
- Mendes CC, Gomes DA, Thompson M, Souto NC, Goes TS, Goes AM, Rodrigues MA, Gomez MV, Nathanson MH, Leite MF: The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca<sup>2+</sup> signals into mitochondria. *J Bio Chem* 2005, 280:40892-40900.
- Rizzuto R, Marchi S, Bonora M, Aguiari P, Bononi A, De Stefani D, Giorgi C, Leo S, Rimessi A, Siviero R, Zecchini E, Pinton P: Ca<sup>2+</sup> transfer from the ER to mitochondria: when, how and why? *Biochimica et Biophysica Acta* 2009, 1787:1342-1351.
- Wu Z, Bowen WD: Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumor cells. *J Biol Chem* 2008, 283:28198-28215.
- Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L, Chastre E, Khan F, Landegren U, Söderberg O, Bootman M, Roderick HL: Phosphorylation of Inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca<sup>2+</sup> release and apoptosis. In Proc Natl Acad Sci Volume 105. USA; 2008:2427-2432.
- Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, Mignery GA, Parys JB, De Smedt H, Distelhorst CW: Targeting Bcl-2-IP<sub>3</sub> receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. *Mol Cell* 2008, 31:255-265.
- Perillo B, Sasso A, Abbondanza C, Palumbo G: 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogenresponsive elements present in the coding sequence. *Mol Cell Biol* 2000, 20:2890-901.
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983, 65:55-63.
- Vanlingen S, Parys JB, Missiaen L, De Smedt H, Wuytack F, Casteels R: Distribution of inositol 1,4,5-trisphosphate receptor isoforms, SERCA isoforms and Ca<sup>2+</sup> binding proteins in RBL-2H3 rat basophilic leukemia cells. *Cell Calcium* 1997, 22:475-486.
- Parys JB, De Smedt H, Missiaen L, Bootman MD, Sienaert I, Casteels R: Rat basophilic leukemia cells as model system for inositol 1,4,5trisphosphate receptor IV, a receptor of the type II family: functional comparison and immunological detection. *Cell Calcium* 1995, 17:239-249.
- Wojcikiewicz RJ: Type I, II, and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types. *J Biol Chem* 1995, 270:11678-11683.

#### doi: 10.1186/1476-4598-9-156

Cite this article as: Szatkowski *et al.*, Inositol 1,4,5-trisphosphate-induced Ca2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth *Molecular Cancer* 2010, **9**:156

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central